 |
|
Ceftriaxone for the Treatment of Serious Infections
Russell W. Steele, MD;
Robert W. Bradsher, MD
Am J Dis Child. 1983;137(11):1044-1047.
Abstract
| |
• Ceftriaxone Is an investigational cephalosporin with a half-life of five to eight hours. In an uncontrolled study, we evaluated its efficacy and safety In 30 pediatric and 12 young adult patients with serious bacterial infections. This agent was administered to children at a dosage of 50 to 75 mg/kg/day intravenously in two divided doses. Those with CNS infections received 100 mg/kg/day. In adults, the dosage was 1 g either once or twice daily. The diseases we treated included pneumonia (17), sepsis (eight), ventriculoperitoneal shunt infections (three), osteomyelitis (three), brain abscess (two), peritonitis (two), and miscellaneous (seven). Clinical cures were achieved in all cases, although one child with cystic fibrosis and Pseudomonas pneumonia had persistent colonization in his sputum. No serious side effects were observed. Although not the agent of choice for many of these pathogens, ceftriaxone appears to represent an important alternative to therapy.
(Am J Dis Child 1983;137:1044-1047)
Author Affiliations
From the Division of Infectious Diseases and Immunology, Departments of Pediatrics (Dr Steele) and Medicine (Dr Bradsher), University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock.
Footnotes
Read before the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, Fla, Oct 5, 1982.
Reprint requests to Arkansas Children's Hospital, 804 Wolfe St, Little Rock, AR 72201 (Dr Steele).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Clinical Characteristics and Outcome of Children With Pneumonia Attributable to Penicillin-susceptible and Penicillin-nonsusceptible Streptococcus pneumoniae
Tan et al.
Pediatrics 1998;102:1369-1375.
ABSTRACT
| FULL TEXT
|
